1 Report Overview

1.1 Global Asthma & COPD Companies Market Overview

1.2 Global Asthma & COPD Companies Market Segmentation

1.3 Why You Should Read this Report

1.4 How this Report Delivers

1.5 Key Questions Answered by this Analytical Report

1.6 Who is This Report for?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2 Introduction to Asthma & COPD Therapies

2.1 COPD Overview

2.1.1 Chronic Obstructive Pulmonary Disease Medications

2.2 Asthma Overview

2.2.1 Desirable inhaler characteristics for treating asthma

2.3 Asthma & COPD Respiratory Inhalers Overview

2.3.1 Nebulizers

2.3.2 Metered Dose Inhaler

2.3.3 Breath-Actuated Pressurised Metered-Dose Inhalers

2.3.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices

2.3.5 Dry powder inhalers (DPIs)

2.3.6 Soft Mist Inhalers

2.4 Asthma & COPD Therapies – Realising Their Potential, Market Drivers

2.4.1 Combination Therapies - Asthma & COPD Products

2.4.2 Triple Combination – Asthma & COPD Products

2.4.3 Opportunities in Telehealth

2.5 Market Restraints

2.6 Asthma & COPD Products: Trends and Developments

2.6.1 E-Technology in Asthma and COPD

3 Leading Asthma & COPD Companies: Overview, 2018

3.1 The Global Asthma & COPD Companies Market In 2018

3.2 Leading Companies in the Asthma & COPD Market, 2018

3.3 How Will Leading Companies’ Market Shares Change to 2029?



4 Leading Asthma & COPD Companies Worldwide, 2018

4.1 Astrazeneca – Company Overview & Analysis

4.1.1 AstraZeneca Marketed Asthma & COPD products

4.1.2 AstraZeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.1.3 AstraZeneca -Asthma & COPD Market Forecast, 2018-2029

4.2 GlaxoSmithKline – Company Overview & Analysis

4.2.1 GlaxoSmithKline Marketed Asthma & COPD products

4.2.2 GlaxoSmithKline, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.2.3 GlaxoSmithKline -Asthma & COPD Market Forecast, 2018-2029

4.3 Boehringer Ingelheim – Company Overview & Analysis

4.3.1 Boehringer Ingelheim Marketed Asthma & COPD products

4.3.2 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.3.3 Boehringer Ingelheim -Asthma & COPD Market Forecast, 2018-2029

4.4 Teva – Company Overview & Analysis

4.4.1 Teva Marketed Asthma & COPD products

4.4.2 Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.4.3 Teva -Asthma & COPD Market Forecast, 2018-2029

4.5 Merck – Company Overview & Analysis

4.5.1 Merck Marketed Asthma & COPD products

4.5.2 Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.5.3 Merck -Asthma & COPD Market Forecast, 2018-2029

4.6 Roche – Company Overview & Analysis

4.6.1 Roche Marketed Asthma & COPD products

4.6.2 Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.6.3 Roche -Asthma & COPD Market Forecast, 2018-2029

4.7 Novartis – Company Overview & Analysis

4.7.1 Novartis Marketed Asthma & COPD products

4.7.2 Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.7.3 Novartis -Asthma & COPD Market Forecast, 2018-2029

4.8 Regeneron Pharmaceuticals (Sanofi)– Company Overview & ANALYSIS

4.8.1 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook

4.8.2 Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2018-2029

4.9 Mundipharma – Company Overview & Analysis

4.9.1 Mundipharma Marketed Asthma & COPD products

4.9.2 Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.10 Theravance Biopharma – Company Overview & Analysis

4.10.1 Theravance Biopharma Marketed Asthma & COPD products

4.10.2 Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.11 Amphastar Pharmaceuticals – Company Overview & Analysis

4.11.1 Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.12 Cipla– Company Overview & Analysis

4.12.1 Cipla Marketed Asthma & COPD products

4.13 Sunovion Pharmaceuticals– Company Overview & Analysis

4.13.1 Sunovion Pharmaceuticals: Marketed Asthma & COPD products

4.13.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.13.3 Sunovion -Asthma & COPD Market Forecast, 2018-2029

4.14 Aerocrine (Circassia)– Company Overview & Analysis

4.14.1 Circassia Marketed Asthma & COPD products

4.14.2 Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.14.3 Circassia -Asthma & COPD Market Forecast, 2018-2029

4.15 Vectura Group – Company Overview & Analysis

4.15.1 Vectura Group Marketed Asthma & COPD products

4.15.2 Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.15.3 Vectura Group -Asthma & COPD Market Forecast, 2018-2029

4.16 Lallemand Pharma Ag– Company Overview & Analysis

4.16.1 Lallemand Pharma AG Marketed Asthma & COPD products

4.16.2 Lallemand Pharma AG, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.16.3 Lallemand Pharma -Asthma & COPD Market Forecast, 2018-2029

4.17 Chiesi Farmaceutici S.P.A. – Company Overview & Analysis

4.17.1 Chiesi Farmaceutici S.p.A Marketed Asthma & COPD Products

4.17.2 Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.17.3 Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2018-2029

4.18 Pulmatrix: Company Overview & Analysis

4.18.1 Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.19 Verona Pharma Plc– Company Overview & Analysis

4.19.1 Verona Pharma plc, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.19.2 Verona Pharma plc -Asthma & COPD Market Forecast, 2018-2029

4.20 Alk-Abelló A/S– Company Overview & Analysis

4.20.1 ALK-Abelló A/S Marketed Asthma & COPD Products

4.20.2 ALK-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook

4.20.3 ALK-Abelló A/S -Asthma & COPD Market Forecast, 2018-2029

5 Conclusions

5.1 Asthma & COPD Products: A Maturing Market

5.2 The Global Asthma & COPD Companies Market In 2019

5.3 Leading Asthma & COPD Companies

5.4 Global Asthma & COPD Products Market Forecast 2019-2029

5.5 The Future of The Asthma & COPD Products Market

5.5.1 Growth in Anti-Inflammatory and Combination Drugs

5.5.2 Personalised Medicine

5.5.3 Unmet Needs in Asthma and COPD

5.6 Strategies for Growth in 2018-2029

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1 Advantages and Disadvantages of the Main Types of Asthma Inhalers

Table 2.2 E-Technology Based Inhalers

Table 3.1 Global Market Forecast: Revenues ($bn), AGR (%) By Leading Companies, 2018-2029

Table 3.2 Leading Companies in Asthma & COPD diseases

Table 3.3 Leading Asthma & COPD Companies: Revenues ($bn) and Market Shares (%), 2019 And 2029

Table 4.1 Astrazeneca: Company Overview

Table 4.2 Astrazeneca: Products Portfolio

Table 4.3 Astrazeneca: Products Pipeline Portfolio

Table 4.4 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.5 Glaxosmithkline: Company Overview

Table 4.6 Glaxosmithkline: Products Portfolio

Table 4.7 Glaxosmithkline: Products Pipeline Portfolio

Table 4.8 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.9 Boehringer Ingelheim: Company Overview

Table 4.10 Boehringer Ingelheim: Products Portfolio

Table 4.11 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.12 Teva: Company Overview

Table 4.13 Teva: Products Portfolio

Table 4.14 Teva: Products Pipeline Portfolio

Table 4.15 Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.16 Merck: Company Overview

Table 4.17 Merck: Products Portfolio

Table 4.18 Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.19 Roche: Company Overview

Table 4.20 Roche: Products Portfolio

Table 4.21 Roche: Products Pipeline Portfolio

Table 4.22 Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.23 Novartis: Company Overview

Table 4.24 Novartis: Products Portfolio

Table 4.25 Novartis: Products Pipeline Portfolio

Table 4.26 Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.27 Regeneron Pharmaceuticals (Sanofi): Company Overview

Table 4.28 Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio

Table 4.29 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.30 Mundipharma: Company Overview

Table 4.31 Mundipharma: Products Portfolio

Table 4.32 Mundipharma: Products Pipeline Portfolio

Table 4.33 Theravance Biopharma: Company Overview

Table 4.34 Theravance Biopharma: Products Portfolio

Table 4.35 Theravance Biopharma: Products Pipeline Portfolio

Table 4.36 Amphastar Pharmaceuticals: Company Overview

Table 4.37 Amphastar Pharmaceuticals: Products Pipeline Portfolio

Table 4.38 Cipla: Company Overview

Table 4.39 Cipla: Products Portfolio

Table 4.40 Sunovion Pharmaceuticals: Company Overview

Table 4.41 Sunovion Pharmaceuticals: Products Portfolio

Table 4.42 Sunovion: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.43 Circassia: Company Overview

Table 4.44 Circassia: Products Portfolio

Table 4.45 Circassia: Products Pipeline Portfolio

Table 4.46 Vectura Group: Company Overview

Table 4.47 Vectura Group: Products Portfolio

Table 4.48 Vectura Group: Products Pipeline Portfolio

Table 4.49 Lallemand Pharma AG: Company Overview

Table 4.50 Lallemand Pharma AG: Products Portfolio

Table 4.51 Lallemand Pharma AG: Products Pipeline Portfolio

Table 4.52 Chiesi Farmaceutici S.P.A: Company Overview

Table 4.53 Chiesi Farmaceutici S.P.A: Products Portfolio

Table 4.54 Chiesi Farmaceutici S.P.A: Products Pipeline Portfolio

Table 4.55 Chiesi Farmaceutici S.P.A: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029

Table 4.56 Pulmatrix: Company Overview

Table 4.57 Pulmatrix: Products Pipeline Portfolio

Table 4.58 Verona Pharma Plc: Company Overview

Table 4.59 Verona Pharma Plc: Products Pipeline Portfolio

Table 4.60 Alk-Abelló A/S: Company Overview

Table 4.61 Alk-Abelló A/S Products Portfolio

Table 4.62 Alk-Abelló A/S: Products Pipeline Portfolio

List of Figures

Figure 1.1 Global Asthma & COPD Companies Market Segmentation Overview, 2019

Figure 2.1 Stepwise Approach to Treatment of COPD

Figure 2.2 Stepwise Approach to Treatment of Asthma

Figure 3.1 Global: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 3.2 Leading Asthma & COPD Drug Manufacturers: Revenue ($bn), 2019

Figure 3.3 Leading Asthma & COPD Drug Manufacturers: Market Share (%), 2019

Figure 3.4 Leading Asthma & COPD Companies: Revenues ($bn), 2029

Figure 3.5 Leading Asthma & COPD Companies: Market Shares (%), 2029

Figure 4.1 AstraZeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.2 GlaxoSmithKline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.3 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.4 Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.5 Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.6 Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.7 Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.8 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.9 Sunovion Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 4.10 Chiesi Farmaceutici Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029

Figure 5.1 World Asthma & COPD Products Market Forecast: Revenues ($bn), 2019-2029